Objective: Concern about adverse effects of progestins on mood has influenced the use of medroxyprogesterone (MPA) and other progestins. In this brief report, we examined whether the administration of MPA leads to depressive symptoms in two groups of perimenopausal and postmenopausal women randomly assigned to treatment with estrogen: one currently experiencing clinical depression and another without depression.
M ore than half of all women initiating treatment with hormone therapy (HT) will stop within the first year of treatment, primarily because of adverse effects. 1<3 Although estrogen given alone 4, 5 and in combination with a progestin 6 has been shown to improve mood in perimenopausal and early postmenopausal women, mood disturbance secondary to HT is also an adverse effect that results in treatment discontinuation. 2 Previous studies have suggested that progestin in the combined HT preparation is responsible for these negative mood effects. 7<12 However, several randomized controlled trials have shown no negative effect of progestin treatment on mood when administered in combination with estrogen therapy (ET) 13<17 or alone. 18 The lack of consistency in these data raises the question of whether progestin therapy is likely to result in negative effects on mood and whether adverse mood effects should be taken into account when discussing the short-term risks of HT. This consideration is particularly important for women with depression, in whom there is heightened concern about the potential for mood destabilization with HT use. However, little is known about the effect of progestins on mood in women who are currently experiencing depression because they have been excluded from previous studies investigating the effects of progestin on mood. Because depression commonly co-occurs with vasomotor symptoms, the primary indication for HT use, 19<21 and women are at greater risk of experiencing a clinical depression during the menopausal transition, 20, 22, 23 the question of whether women with depression are especially susceptible to mood deterioration when treated with progestins is particularly relevant.
In this brief report, we examine whether the administration of medroxyprogesterone (MPA), the most commonly prescribed progestin, leads to depressive symptoms in perimenopausal and postmenopausal women who were treated with 17A-estradiol in two randomized placebo-controlled trials. This analysis was conducted in two groups of women: one that included women who were currently experiencing clinical depression as part of the indication for ET, 24 and another that included women who were not depressed but sought treatment with ET because of cognitive difficulties. 25 We hypothesized that depressed, but not nondepressed, women would be susceptible to the negative effects of MPA on their mood.
METHODS

Study participants and design
This analysis examines the effect of MPA 10 mg/day on mood in 40-to 60-year-old perimenopausal and postmenopausal women with menopause-related symptoms in two double-blind randomized placebo-controlled trials of ET. 24, 25 Both trials enrolled women from the community who were perimenopausal (in the early or late menopausal transition stage), 26 postmenopausal (natural or surgical), or hysterectomized without bilateral oophorectomy if serum folliclestimulating hormone levels were higher than 25 IU/L. Both trials involved randomized assignment to unopposed transdermal 17A-estradiol 0.05 mg/day or placebo. At the end of the trial, treatment assignment was revealed, and all women who had a uterus and received ET were treated with openlabel MPA 10 mg for 14 days. The Partners Healthcare Systems Institutional Review Board approved both study protocols, and written informed consent was obtained from all participants. Further details describing these two trials have been reported elsewhere. 24, 25 The two trials differed primarily on the symptom profile required for eligibility. The first trial was restricted to healthy nondepressed women (n = 52) who perceived cognitive problems they attributed to the menopausal transition. 25 The goal of the trial was to determine whether ET alters specific cognitive processes involved in verbal and visual learning and memory and frontal executive function. Women with depression and any other psychiatric illness were excluded using the standardized clinician-rated Structured Clinical Interview for DSM-IV Disorders. 27 Women with hot flashes and sleep disturbance were not excluded, and most women experienced these symptoms. The randomization involved double-blinded assignment to ET or placebo for 12 weeks, such that 26 women were assigned to treatment with ET.
The second trial was restricted to women with clinical depression (n = 72) who were concurrently experiencing hot flashes and sleep disturbance attributed to nocturnal hot flashes. 24 Using the Structured Clinical Interview for DSM-IV Disorders, women currently experiencing clinical depression (major depression, 71%; dysthymia or minor depression, 29%) and who had a score of 15 to 31 on the MontgomeryÅsberg Depression Rating Scale 28 were enrolled. Participants were randomly assigned to one of three treatments (ET, zolpidem 10 mg/day, or placebo) in a 2:2:1 ratio for 8 weeks such that 27 women received ET. The goal of the trial was to determine whether depression would improve in women treated with ET more than in those receiving a specific treatment of sleep disruption (zolpidem).
In both trials, depression symptoms were assessed at study entry, at the end of the double-blinded ET treatment, and at the end of 14 days of MPA using the Beck Depression Inventory (BDI), a widely used 21-item self-report scale that records the severity of depression symptoms during the previous week (range, 0 to 63; with a higher score indicating greater symptom burden). 29 BDI scores range from minimal (scores, 0 to 9) to mild (10 to 16), moderate (17 to 29), and severe (30 to 63) depressive symptoms, with a score of 18 or higher typically used to indicate clinically relevant depression symptoms. 30 Only women treated with MPA underwent the additional follow-up assessment of mood after completion of each trial. This analysis reports on changes in BDI scores for women discontinuing ET who then received treatment with MPA.
Analysis
The analysis was conducted using nonparametric tests because of the small sample size. Within-group comparisons were made using Wilcoxon signed rank tests, and betweengroup comparisons were made using the Wilcoxon rank sum test. To adjust for characteristics that differed between groups (ie, education status, hot flashes, or night sweats on MPA), the change in BDI scores on MPA was Box-Cox transformed because of nonnormal distribution, and linear regression analysis was conducted on the transformed dependent measure. All analyses were conducted using STATA (College Station, TX) with > = 0.05.
RESULTS
Participants
Of 26 nondepressed women randomly assigned to ET, 24 (92.3%) received a 14-day course of MPA after completing the 12-week course of ET. Two women did not receive MPA because they had previously undergone a hysterectomy. In the trial for depressed women, 21 (77.8%) of 27 women assigned to ET completed the 8-week course of treatment, and 14 (66.7%) of the 21 received a 14-day course of MPA. Seven women who completed the course of ET did not receive MPA because they had undergone a hysterectomy, whereas two women were lost-to-follow-up during the MPA phase of the study.
Within each trial, there were no differences between the ET group and other treatment groups in demographic characteristics, menopause status, or baseline levels of folliclestimulating hormone, sleep quality, body mass index, or depressive symptoms. Detailed descriptions of study population characteristics are available elsewhere. 24, 25 When the subgroup of women treated with MPA in each trial was compared, the only characteristics that differed between the depressed and nondepressed study populations were that the nondepressed group was more likely to have graduated college and less likely to experience hot flashes at study entry and on MPA (Table 1) . Briefly, both groups included predominately perimenopausal women with a mean (SD) overall age, for both groups together, of 50.6 (3.4) years. No participant in either group discontinued MPA because of adverse effects.
Depressive symptoms on estradiol and medroxyprogesterone
Consistent with eligibility criteria for each study, the depressed group had higher BDI scores at study entry (median [interquartile range; IQR], 17 [15] [16] [17] [18] [19] [20] [21] Despite the higher BDI scores with estradiol in the depressed group before MPA therapy, the extent to which depressive symptoms changed with MPA did not differ between groups (P = 0.25). Adjustment for education status and hot flashes/night sweats with MPA did not alter these findings (P = 0.96).
DISCUSSION
The results of this brief report indicate that MPA does not increase depressive symptoms in perimenopausal and postmenopausal women treated sequentially with estradiol and then MPA, even among women receiving ET for treatment of depression. We found that improvements in mood with ET among women who were and were not experiencing clinical depression were not lost when ET was discontinued and when MPA was started, even when hot flashes and night sweats recurred. To our knowledge, this is the first study to investigate the effects of MPA on mood specifically in a depressed population. Our findings suggest that MPA can be used safely in depressed and in nondepressed women and that progestins should not be withheld from depressed women because of an expectation that the progestin will make them more depressed. Continuous data are presented as mean T SD, and categorical data are presented as n (%). For continuous data, P values represent between-group differences using the Wilcoxon signed rank test and the Wilcoxon rank sum test for within-group differences; Fisher exact tests were used for categorical data. BMI, body mass index; IQR, interquartile range; BDI, Beck Depression Inventory. e Data missing for two depressed participants.
f P e 0.007 for within-group analyses for both groups. Our results are consistent with previous data in nondepressed women showing that the administration of progestins does not detract from the positive mood effects of estrogen therapy. 13<18 These studies include a variety of different progestin and estrogen preparations and doses, making direct comparison challenging. Studies using MPA specifically have shown that mood does not worsen with MPA when co-administered with 17A-estradiol 50 to 100 Kg/day, 14, 16 conjugated equine estrogens 0.625 mg/day, 17 or no estrogen. 18 In contrast, studies finding an adverse effect of MPA on mood have observed that the effect varies by dose of the estrogen preparation, with mood worsening occurring when MPA was administered together with only the highest (3 mg/day, but not 2 mg/day) doses of 17A-estradiol, 31 and lower (0.625 mg/day) but not higher (1.25 mg/day) doses of conjugated equine estrogens, 12 suggesting that the nature of the mood response may vary with the dose and preparation of the co-administered ET.
This study is limited by its sample size, although the size of our study population is within the same range as that studied in most other investigations of the effect of progestins on mood.
7<9,11<15, 17, 18 The only large intervention study that has specifically investigated the mood effects of progestins found no effect of a variety of progestin preparations on mood in a sample of nondepressed women. 16 It is also notable that our depressed study population had BDI scores within the mildto-moderate range of depressive symptoms at baseline, which were subsequently reduced to minimal-to-mild levels with ET and then remained at the minimal-to-mild levels with MPA. It is therefore unknown whether our findings are generalizable to women with more severe depressive episodes or those who have previously demonstrated susceptibility of their mood to fluctuations in reproductive hormones, such as postpartum depression, premenstrual dysphoric disorder, or onset of depression in perimenopause. The generalizability of our findings to women using MPA concurrent with ET, rather than sequentially with ET, is also unknown. However, although concurrent withdrawal of ET may have confounded our results, ET discontinuation would be expected to worsen, rather than improve, mood. This study addresses the mood effects related to the specific dose and preparation of progestin that was administered for only a brief period of time. Further randomized trials, with different types of progestins used for longer periods of time, are warranted to address the generalizability of our findings to other progestins and the effects of chronic progestin therapy on mood.
CONCLUSIONS
In summary, the results of our study indicate that MPA administered for 2 weeks after discontinuation of 17A-estradiol does not have adverse effects on depressive symptoms in perimenopausal and postmenopausal women who are currently experiencing clinical depression, as well as those without depression, even in the context of persistent hot flashes and night sweats. These findings support the use of MPA for endometrial protection as part of an HT regimen in all women, regardless of depression status.
